Kinaset Therapeutics raised $103 million in an oversubscribed Series B to advance its inhaled respiratory therapeutic candidate.
- Amount
- $103M
- Stage
- Series B
- Announced
- 10 January 2026
- Leads
- RA Capital Management, Forge Life Science Partners
- Other investors
- EQT Life Sciences, Vivo Capital, Schroders Capital, Willett Advisors, Pictet Alternative Advisors, Sixty Degree Capital, Atlas Venture, 5AM Ventures, Gimv
- Use of funds
- Advance frevecitinib, an inhaled candidate, through Phase 2 studies in severe asthma.
- Checked
- Amount and date checked against the press source